Table 1.
Src inhibitors with other agents in clinical trials.
| Drug | Phase | Tumor type | Combination agent |
|---|---|---|---|
| Dasatinib | II | Advanced-NSCLC/Colorectal/Pancreatic/HNSCC/Breast/SCLC/Melanoma | — |
| II | Resectable NSCLC/HNSCC | Erlotinib | |
| I-II | Advanced NSCLC | Erlotinib | |
| I | Breast | Capecitabine | |
| I | Breast | Paclitaxel | |
| I-II | Prostate/castration resistant prostate cancer | Docetaxel | |
| I | Colon | FOLFOX6/Cetuximab | |
|
| |||
| Saracatinib | II | Prostate/Pancreatic/Osteosarcoma/Soft tissue sarcoma/Melanoma/Gastration-resistant prostate cancer/Thymoma/Colorectal/HNSCC | — |
| II | Advanced NSCLC/SCLC | Carboplatin/Paclitaxel | |
| I | Advanced solid tumor | Cediranib | |
| I-II | Pancreatic | Gemcitabine | |
| II | Ovarian | Carboplatin | |
| II | Prostate/Breast with bone metastasis | Zoledronic acid | |
|
| |||
| Bosutinib | II | Breast | — |
| II | Breast | Exemestane | |
| II | Breast | Letrozole/Capecitabine | |
| I-II | Advanced solid tumor | Capecitabine | |
|
| |||
| XL228 | I | Advanced solid tumor | — |
|
| |||
| KX2-391 | I | Advanced solid tumor/Lymphoma | — |
|
| |||
| AZM475271 | I-II | Pancreatic | — |
|
| |||
| XL999 | I | Advanced solid tumor | — |